List of Tables
Table 1. Myelodysplastic Syndrome (MDS) Treatment Market Trends
Table 2. Myelodysplastic Syndrome (MDS) Treatment Market Drivers & Opportunity
Table 3. Myelodysplastic Syndrome (MDS) Treatment Market Challenges
Table 4. Myelodysplastic Syndrome (MDS) Treatment Market Restraints
Table 5. Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Company (2019-2024)
Table 7. Key Companies Myelodysplastic Syndrome (MDS) Treatment Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Myelodysplastic Syndrome (MDS) Treatment Product Type
Table 9. Key Companies Time to Begin Mass Production of Myelodysplastic Syndrome (MDS) Treatment
Table 10. Global Myelodysplastic Syndrome (MDS) Treatment Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Myelodysplastic Syndrome (MDS) Treatment as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Myelodysplastic Syndrome (MDS) Treatment Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Myelodysplastic Syndrome (MDS) Treatment Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global Myelodysplastic Syndrome (MDS) Treatment Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global Myelodysplastic Syndrome (MDS) Treatment Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Myelodysplastic Syndrome (MDS) Treatment Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global Myelodysplastic Syndrome (MDS) Treatment Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global Myelodysplastic Syndrome (MDS) Treatment Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global Myelodysplastic Syndrome (MDS) Treatment Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global Myelodysplastic Syndrome (MDS) Treatment Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global Myelodysplastic Syndrome (MDS) Treatment Sales Value by Region (2019-2024) & (%)
Table 27. Global Myelodysplastic Syndrome (MDS) Treatment Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions Myelodysplastic Syndrome (MDS) Treatment Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions Myelodysplastic Syndrome (MDS) Treatment Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions Myelodysplastic Syndrome (MDS) Treatment Sales Value, (2025-2030) & (US$ Million)
Table 31. Novartis AG Basic Information List
Table 32. Novartis AG Description and Business Overview
Table 33. Novartis AG Myelodysplastic Syndrome (MDS) Treatment Products, Services and Solutions
Table 34. Revenue (US$ Million) in Myelodysplastic Syndrome (MDS) Treatment Business of Novartis AG (2019-2024)
Table 35. Novartis AG Recent Developments
Table 36. Celgene Corporation Basic Information List
Table 37. Celgene Corporation Description and Business Overview
Table 38. Celgene Corporation Myelodysplastic Syndrome (MDS) Treatment Products, Services and Solutions
Table 39. Revenue (US$ Million) in Myelodysplastic Syndrome (MDS) Treatment Business of Celgene Corporation (2019-2024)
Table 40. Celgene Corporation Recent Developments
Table 41. Otsuka Pharmaceutical Co., Ltd Basic Information List
Table 42. Otsuka Pharmaceutical Co., Ltd Description and Business Overview
Table 43. Otsuka Pharmaceutical Co., Ltd Myelodysplastic Syndrome (MDS) Treatment Products, Services and Solutions
Table 44. Revenue (US$ Million) in Myelodysplastic Syndrome (MDS) Treatment Business of Otsuka Pharmaceutical Co., Ltd (2019-2024)
Table 45. Otsuka Pharmaceutical Co., Ltd Recent Developments
Table 46. Sandoz Inc Basic Information List
Table 47. Sandoz Inc Description and Business Overview
Table 48. Sandoz Inc Myelodysplastic Syndrome (MDS) Treatment Products, Services and Solutions
Table 49. Revenue (US$ Million) in Myelodysplastic Syndrome (MDS) Treatment Business of Sandoz Inc (2019-2024)
Table 50. Sandoz Inc Recent Developments
Table 51. Dr Reddys Laboratories Limited Basic Information List
Table 52. Dr Reddys Laboratories Limited Description and Business Overview
Table 53. Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Treatment Products, Services and Solutions
Table 54. Revenue (US$ Million) in Myelodysplastic Syndrome (MDS) Treatment Business of Dr Reddys Laboratories Limited (2019-2024)
Table 55. Dr Reddys Laboratories Limited Recent Developments
Table 56. Pharmascience Inc Basic Information List
Table 57. Pharmascience Inc Description and Business Overview
Table 58. Pharmascience Inc Myelodysplastic Syndrome (MDS) Treatment Products, Services and Solutions
Table 59. Revenue (US$ Million) in Myelodysplastic Syndrome (MDS) Treatment Business of Pharmascience Inc (2019-2024)
Table 60. Pharmascience Inc Recent Developments
Table 61. Accord Healthcare Ltd Basic Information List
Table 62. Accord Healthcare Ltd Description and Business Overview
Table 63. Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Treatment Products, Services and Solutions
Table 64. Revenue (US$ Million) in Myelodysplastic Syndrome (MDS) Treatment Business of Accord Healthcare Ltd (2019-2024)
Table 65. Accord Healthcare Ltd Recent Developments
Table 66. Mylan N.V. Basic Information List
Table 67. Mylan N.V. Description and Business Overview
Table 68. Mylan N.V. Myelodysplastic Syndrome (MDS) Treatment Products, Services and Solutions
Table 69. Revenue (US$ Million) in Myelodysplastic Syndrome (MDS) Treatment Business of Mylan N.V. (2019-2024)
Table 70. Mylan N.V. Recent Developments
Table 71. Takeda Pharmaceutical Company Limited Basic Information List
Table 72. Takeda Pharmaceutical Company Limited Description and Business Overview
Table 73. Takeda Pharmaceutical Company Limited Myelodysplastic Syndrome (MDS) Treatment Products, Services and Solutions
Table 74. Revenue (US$ Million) in Myelodysplastic Syndrome (MDS) Treatment Business of Takeda Pharmaceutical Company Limited (2019-2024)
Table 75. Takeda Pharmaceutical Company Limited Recent Developments
Table 76. Bristol-Myers Squibb Basic Information List
Table 77. Bristol-Myers Squibb Description and Business Overview
Table 78. Bristol-Myers Squibb Myelodysplastic Syndrome (MDS) Treatment Products, Services and Solutions
Table 79. Revenue (US$ Million) in Myelodysplastic Syndrome (MDS) Treatment Business of Bristol-Myers Squibb (2019-2024)
Table 80. Bristol-Myers Squibb Recent Developments
Table 81. LUPIN Basic Information List
Table 82. LUPIN Description and Business Overview
Table 83. LUPIN Myelodysplastic Syndrome (MDS) Treatment Products, Services and Solutions
Table 84. Revenue (US$ Million) in Myelodysplastic Syndrome (MDS) Treatment Business of LUPIN (2019-2024)
Table 85. LUPIN Recent Developments
Table 86. Pfizer Inc Basic Information List
Table 87. Pfizer Inc Description and Business Overview
Table 88. Pfizer Inc Myelodysplastic Syndrome (MDS) Treatment Products, Services and Solutions
Table 89. Revenue (US$ Million) in Myelodysplastic Syndrome (MDS) Treatment Business of Pfizer Inc (2019-2024)
Table 90. Pfizer Inc Recent Developments
Table 91. Amgen Inc Basic Information List
Table 92. Amgen Inc Description and Business Overview
Table 93. Amgen Inc Myelodysplastic Syndrome (MDS) Treatment Products, Services and Solutions
Table 94. Revenue (US$ Million) in Myelodysplastic Syndrome (MDS) Treatment Business of Amgen Inc (2019-2024)
Table 95. Amgen Inc Recent Developments
Table 96. Onconova Therapeutics Basic Information List
Table 97. Onconova Therapeutics Description and Business Overview
Table 98. Onconova Therapeutics Myelodysplastic Syndrome (MDS) Treatment Products, Services and Solutions
Table 99. Revenue (US$ Million) in Myelodysplastic Syndrome (MDS) Treatment Business of Onconova Therapeutics (2019-2024)
Table 100. Onconova Therapeutics Recent Developments
Table 101. Astex Pharmaceutical Basic Information List
Table 102. Astex Pharmaceutical Description and Business Overview
Table 103. Astex Pharmaceutical Myelodysplastic Syndrome (MDS) Treatment Products, Services and Solutions
Table 104. Revenue (US$ Million) in Myelodysplastic Syndrome (MDS) Treatment Business of Astex Pharmaceutical (2019-2024)
Table 105. Astex Pharmaceutical Recent Developments
Table 106. Helsinn Healthcare SA Basic Information List
Table 107. Helsinn Healthcare SA Description and Business Overview
Table 108. Helsinn Healthcare SA Myelodysplastic Syndrome (MDS) Treatment Products, Services and Solutions
Table 109. Revenue (US$ Million) in Myelodysplastic Syndrome (MDS) Treatment Business of Helsinn Healthcare SA (2019-2024)
Table 110. Helsinn Healthcare SA Recent Developments
Table 111. Abbott Basic Information List
Table 112. Abbott Description and Business Overview
Table 113. Abbott Myelodysplastic Syndrome (MDS) Treatment Products, Services and Solutions
Table 114. Revenue (US$ Million) in Myelodysplastic Syndrome (MDS) Treatment Business of Abbott (2019-2024)
Table 115. Abbott Recent Developments
Table 116. Boehringer Ingelheim International GmbH, Basic Information List
Table 117. Boehringer Ingelheim International GmbH, Description and Business Overview
Table 118. Boehringer Ingelheim International GmbH, Myelodysplastic Syndrome (MDS) Treatment Products, Services and Solutions
Table 119. Revenue (US$ Million) in Myelodysplastic Syndrome (MDS) Treatment Business of Boehringer Ingelheim International GmbH, (2019-2024)
Table 120. Boehringer Ingelheim International GmbH, Recent Developments
Table 121. Johnson & Johnson Private Limited. Basic Information List
Table 122. Johnson & Johnson Private Limited. Description and Business Overview
Table 123. Johnson & Johnson Private Limited. Myelodysplastic Syndrome (MDS) Treatment Products, Services and Solutions
Table 124. Revenue (US$ Million) in Myelodysplastic Syndrome (MDS) Treatment Business of Johnson & Johnson Private Limited. (2019-2024)
Table 125. Johnson & Johnson Private Limited. Recent Developments
Table 126. MEI Pharma Inc. Basic Information List
Table 127. MEI Pharma Inc. Description and Business Overview
Table 128. MEI Pharma Inc. Myelodysplastic Syndrome (MDS) Treatment Products, Services and Solutions
Table 129. Revenue (US$ Million) in Myelodysplastic Syndrome (MDS) Treatment Business of MEI Pharma Inc. (2019-2024)
Table 130. MEI Pharma Inc. Recent Developments
Table 131. Aprea Therapeutics Basic Information List
Table 132. Aprea Therapeutics Description and Business Overview
Table 133. Aprea Therapeutics Myelodysplastic Syndrome (MDS) Treatment Products, Services and Solutions
Table 134. Revenue (US$ Million) in Myelodysplastic Syndrome (MDS) Treatment Business of Aprea Therapeutics (2019-2024)
Table 135. Aprea Therapeutics Recent Developments
Table 136. Reddy's Laboratories Ltd. Basic Information List
Table 137. Reddy's Laboratories Ltd. Description and Business Overview
Table 138. Reddy's Laboratories Ltd. Myelodysplastic Syndrome (MDS) Treatment Products, Services and Solutions
Table 139. Revenue (US$ Million) in Myelodysplastic Syndrome (MDS) Treatment Business of Reddy's Laboratories Ltd. (2019-2024)
Table 140. Reddy's Laboratories Ltd. Recent Developments
Table 141. AbbVie Inc. Basic Information List
Table 142. AbbVie Inc. Description and Business Overview
Table 143. AbbVie Inc. Myelodysplastic Syndrome (MDS) Treatment Products, Services and Solutions
Table 144. Revenue (US$ Million) in Myelodysplastic Syndrome (MDS) Treatment Business of AbbVie Inc. (2019-2024)
Table 145. AbbVie Inc. Recent Developments
Table 146. Syros Pharmaceuticals Basic Information List
Table 147. Syros Pharmaceuticals Description and Business Overview
Table 148. Syros Pharmaceuticals Myelodysplastic Syndrome (MDS) Treatment Products, Services and Solutions
Table 149. Revenue (US$ Million) in Myelodysplastic Syndrome (MDS) Treatment Business of Syros Pharmaceuticals (2019-2024)
Table 150. Syros Pharmaceuticals Recent Developments
Table 151. Acceleron Pharma, Inc. Basic Information List
Table 152. Acceleron Pharma, Inc. Description and Business Overview
Table 153. Acceleron Pharma, Inc. Myelodysplastic Syndrome (MDS) Treatment Products, Services and Solutions
Table 154. Revenue (US$ Million) in Myelodysplastic Syndrome (MDS) Treatment Business of Acceleron Pharma, Inc. (2019-2024)
Table 155. Acceleron Pharma, Inc. Recent Developments
Table 156. Key Raw Materials Lists
Table 157. Raw Materials Key Suppliers Lists
Table 158. Myelodysplastic Syndrome (MDS) Treatment Downstream Customers
Table 159. Myelodysplastic Syndrome (MDS) Treatment Distributors List
Table 160. Research Programs/Design for This Report
Table 161. Key Data Information from Secondary Sources
Table 162. Key Data Information from Primary Sources
Table 163. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Myelodysplastic Syndrome (MDS) Treatment Product Picture
Figure 2. Global Myelodysplastic Syndrome (MDS) Treatment Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Myelodysplastic Syndrome (MDS) Treatment Sales Value (2019-2030) & (US$ Million)
Figure 4. Myelodysplastic Syndrome (MDS) Treatment Report Years Considered
Figure 5. Global Myelodysplastic Syndrome (MDS) Treatment Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Myelodysplastic Syndrome (MDS) Treatment Revenue in 2023
Figure 7. Myelodysplastic Syndrome (MDS) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. Azacitidine Picture
Figure 9. Lenalidomide Picture
Figure 10. Decitabine Picture
Figure 11. Deferasirox Picture
Figure 12. Global Myelodysplastic Syndrome (MDS) Treatment Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 13. Global Myelodysplastic Syndrome (MDS) Treatment Sales Value Market Share by Type, 2023 & 2030
Figure 14. Product Picture of Refractory Cytopenia with Unilineage Dysplasia
Figure 15. Product Picture of Refractory Anemia with Ringed Sideroblasts
Figure 16. Product Picture of Others
Figure 17. Global Myelodysplastic Syndrome (MDS) Treatment Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 18. Global Myelodysplastic Syndrome (MDS) Treatment Sales Value Market Share by Application, 2023 & 2030
Figure 19. North America Myelodysplastic Syndrome (MDS) Treatment Sales Value (2019-2030) & (US$ Million)
Figure 20. North America Myelodysplastic Syndrome (MDS) Treatment Sales Value by Country (%), 2023 VS 2030
Figure 21. Europe Myelodysplastic Syndrome (MDS) Treatment Sales Value (2019-2030) & (US$ Million)
Figure 22. Europe Myelodysplastic Syndrome (MDS) Treatment Sales Value by Country (%), 2023 VS 2030
Figure 23. Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Sales Value (2019-2030) & (US$ Million)
Figure 24. Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Sales Value by Country (%), 2023 VS 2030
Figure 25. South America Myelodysplastic Syndrome (MDS) Treatment Sales Value (2019-2030) & (US$ Million)
Figure 26. South America Myelodysplastic Syndrome (MDS) Treatment Sales Value by Country (%), 2023 VS 2030
Figure 27. Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Sales Value (2019-2030) & (US$ Million)
Figure 28. Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Sales Value by Country (%), 2023 VS 2030
Figure 29. Key Countries/Regions Myelodysplastic Syndrome (MDS) Treatment Sales Value (%), (2019-2030)
Figure 30. United States Myelodysplastic Syndrome (MDS) Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 31. United States Myelodysplastic Syndrome (MDS) Treatment Sales Value by Type (%), 2023 VS 2030
Figure 32. United States Myelodysplastic Syndrome (MDS) Treatment Sales Value by Application (%), 2023 VS 2030
Figure 33. Europe Myelodysplastic Syndrome (MDS) Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 34. Europe Myelodysplastic Syndrome (MDS) Treatment Sales Value by Type (%), 2023 VS 2030
Figure 35. Europe Myelodysplastic Syndrome (MDS) Treatment Sales Value by Application (%), 2023 VS 2030
Figure 36. China Myelodysplastic Syndrome (MDS) Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 37. China Myelodysplastic Syndrome (MDS) Treatment Sales Value by Type (%), 2023 VS 2030
Figure 38. China Myelodysplastic Syndrome (MDS) Treatment Sales Value by Application (%), 2023 VS 2030
Figure 39. Japan Myelodysplastic Syndrome (MDS) Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 40. Japan Myelodysplastic Syndrome (MDS) Treatment Sales Value by Type (%), 2023 VS 2030
Figure 41. Japan Myelodysplastic Syndrome (MDS) Treatment Sales Value by Application (%), 2023 VS 2030
Figure 42. South Korea Myelodysplastic Syndrome (MDS) Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 43. South Korea Myelodysplastic Syndrome (MDS) Treatment Sales Value by Type (%), 2023 VS 2030
Figure 44. South Korea Myelodysplastic Syndrome (MDS) Treatment Sales Value by Application (%), 2023 VS 2030
Figure 45. Southeast Asia Myelodysplastic Syndrome (MDS) Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 46. Southeast Asia Myelodysplastic Syndrome (MDS) Treatment Sales Value by Type (%), 2023 VS 2030
Figure 47. Southeast Asia Myelodysplastic Syndrome (MDS) Treatment Sales Value by Application (%), 2023 VS 2030
Figure 48. India Myelodysplastic Syndrome (MDS) Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 49. India Myelodysplastic Syndrome (MDS) Treatment Sales Value by Type (%), 2023 VS 2030
Figure 50. India Myelodysplastic Syndrome (MDS) Treatment Sales Value by Application (%), 2023 VS 2030
Figure 51. Myelodysplastic Syndrome (MDS) Treatment Industrial Chain
Figure 52. Myelodysplastic Syndrome (MDS) Treatment Manufacturing Cost Structure
Figure 53. Channels of Distribution (Direct Sales, and Distribution)
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
